Wells Fargo & Company MN decreased its holdings in shares of Cytosorbents Corp (NASDAQ:CTSO) by 58.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,213 shares of the medical research company’s stock after selling 34,883 shares during the quarter. Wells Fargo & Company MN owned approximately 0.08% of Cytosorbents worth $167,000 at the end of the most recent quarter.
Separately, Skylands Capital LLC raised its stake in Cytosorbents by 7.0% during the second quarter. Skylands Capital LLC now owns 680,600 shares of the medical research company’s stock worth $4,499,000 after acquiring an additional 44,550 shares during the period. 26.29% of the stock is owned by institutional investors and hedge funds.
In other news, CFO Kathleen P. Bloch purchased 6,500 shares of the company’s stock in a transaction on Friday, August 16th. The shares were bought at an average price of $4.83 per share, for a total transaction of $31,395.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.60% of the stock is currently owned by company insiders.
Shares of NASDAQ:CTSO opened at $4.67 on Friday. The firm’s 50 day moving average is $4.93 and its two-hundred day moving average is $6.29. Cytosorbents Corp has a 52 week low of $3.68 and a 52 week high of $12.00. The company has a debt-to-equity ratio of 0.87, a quick ratio of 3.00 and a current ratio of 3.21.
Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. Cytosorbents had a negative net margin of 72.43% and a negative return on equity of 105.97%. The company had revenue of $6.23 million for the quarter, compared to analyst estimates of $6.53 million. On average, sell-side analysts predict that Cytosorbents Corp will post -0.53 earnings per share for the current fiscal year.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Featured Article: Should You Consider an Index Fund?
Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Corp (NASDAQ:CTSO).
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.